A New Line Of Sight
Into Targeted Cancer Therapies

Our team is comprised of leading industry experts with deep radiotherapy development experience

Curtis Nelson, BBA
Board Chairman

Curtis Nelson, serves as the current Chairman of the Board at Viewpoint and is concurrently the President and CEO of EDC, Inc., a business accelerator he founded in 2003, as well as President and co-founder of the Iowa Venture Capital Association. As a 1974 graduate from the University of Iowa, Mr. Nelson holds a BBA in Marketing and is also the author of The Recipe for Business Success. Mr. Nelson has over thirty-five years of successful national and international business creation and leadership experience – directing the development and successful launch of over 100 new businesses and more than 500 new products for the medical, health, communications, IT, military, transportation, food, and gardening industries worldwide. Mr. Nelson’s areas of expertise include starting-up and financing through a product development life cycle as well as management consulting in financials. Mr. Nelson is a successful entrepreneur, investor, seasoned public speaker, consultant, and three-time veteran of Inc. Magazine’s 500 Fastest-Growing Private Companies® list (#48, #67, #225).

Thomas A. Raffin, M.D.
Board Member

Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics and Founder and Director Emeritus of the Stanford University Asia Medical Fund.  Tom received the Stanford Medical School RISE Award as alumni of the year in 2014. He has written over 200 articles, chapters and books. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. Tom has represented THP on the boards of InvisALERT, Akoya Biosciences (NASDAQ:AKYA), AngioScore (acquired by Spectranetics), Confirma (acquired by Merge), LDR Spine (NASDAQ:LDRH), PneumRx (acquired by BTG Plc), Freedom Innovations (acquired by Health Evolution Partners) and Magstim. He was an observer on the boards of Estech (acquired by AtriCure) and Vidacare (acquired by Teleflex). He is Co-Chairman of the Board of the National AIDS Memorial in Golden Gate Park.

Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and completed his medical residency at the Brigham and Women’s Hospital in Boston.

Cameron Gray, PhD
Board Member

Dr. Cameron Gray is the Founder and Chief Executive Officer of Alcedo Capital. Prior to founding Alcedo in 2019, he served as CEO for Cue Biopharma, a clinical-stage biopharmaceutical company engineering a new class of injectable biologics to transform the treatment of cancer, infectious disease, and autoimmune disease. Over the course of his career he has also served as the Managing Director at MDB Capital Group, CEO and a member of the board of directors of Endeavor IP, Inc., an intellectual property services and patent licensing company, and Senior Vice President at ICAP Patent Brokerage, LLC, where he managed its life sciences and Asia Pacific businesses.

Dr. Gray has a J.D. from George Washington University School of Law, a Ph.D. in biophysics from the University of Virginia, and a B.A. in physics from Princeton University.

Charles Link, MD
Board Member

Charles Link, MD FACP is a medical oncologist with deep experience in medical innovation. Most recently, Dr. Link was the CEO, CSO, Chairman and founder of NewLink Genetics, a pioneering immunotherapy company that discovered, developed and commercialized novel immuno-oncology product candidates, including checkpoint inhibitors and cellular immunotherapies. At its height, NewLink’s market cap exceeded $1.3B. Dr. Link struck multiple deals worth hundreds of millions of dollars with companies such as Novartis and Roche. Charles led the development of Merck’s EVERBO, the first Ebola vaccine to receive FDA Approval. Previously, Dr. Link was an attending physician at the National Cancer Institute. He has authored more than 170 peer reviewed papers and has received millions in funding from National Institute of Health, National Cancer Institute, American Cancer Society, and others. Charles received an MD from Stanford University and he attended the Air Force Academy.

Frank Morich, MD, PhD
Board Member

Dr. Frank Morich is a biopharmaceutical professional with more than 35 years of industry experience. He currently serves on the board of directors for MorphoSys (since May 2015) and served as a board member for Innate Pharma between 2004-2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board work, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to industry.